William E. Leuchtenburg, a leading scholar of Franklin Roosevelt and the Great Depression, has died at age 102.

Winter depression can take a toll on your mind and body. Local health experts say depression is something you should take ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

(HealthDay News) — The US Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

The U.S. Food and Drug Administration has approved a nose spray to help treat depression, Johnson & Johnson announced Tuesday ...

Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven’t responded to oral ...

The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...

The way obesity is diagnosed needs to become more sophisticated, an international commission has concluded. Using body-mass index to tell who is overweight or obese is not reliable and can result ...

Johnson & Johnson (NYSE ... point happened after the late 2021 approval for the treatment of bipolar depression. Caplyta is on track to generate nearly $700 million in net sales in 2024 and ...

Johnson & Johnson will pay Intra-Cellular shareholders ... which treats schizophrenia and bipolar I and II depression. The company also has other drugs in the pipeline to treat Alzheimer's Disease ...